Squarepoint
BPMC

Squarepoint’s Blueprint Medicines BPMC Stock Holding History

Squarepoint’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,100
Closed -$270K – 4616
2024
Q4 		$270K Buy
+3,100
New +$284K ﹤0.01% 4233
2024
Q3 		– Sell
-2,400
Closed -$259K – 4136
2024
Q2 		$259K Sell
2,400
-3,900
-62% -$390K ﹤0.01% 3510
2024
Q1 		$598K Buy
+6,300
New +$540K ﹤0.01% 2929

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Squarepoint's BPMC Position: Q3 2025 in Review

Squarepoint sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 130,066 shares — an estimated $16.7M sold.

Squarepoint first reported a position in BPMC in Q4 2016 and held it in 23 quarters. The position peaked at $23.1M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Squarepoint reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 130,066 Blueprint Medicines shares in Q3 2025, an estimated $16.7M.
  • Squarepoint first reported a position in Blueprint Medicines in Q4 2016 and held it in 23 quarters.
  • Squarepoint's Blueprint Medicines position peaked at $23.1M in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.